Corporate & Investor Presentation

Capital allocation $ in millions 4Q20 Capital Allocation Cash and cash equivalents $463.2 Debt $1,176.1 Higher priority Organic business growth Net debt $712.9 Free cash flow Free cash flow $312.3 Unused borrowing capacity $1,090.0 NOTE: Values may not calculate due to rounding During 4Q20 $52.5M invested in R&D (7% of revenue) Paid $56.5M in dividends to shareholders 36 © 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 * Dividends Share buybacks* Share buyback program currently suspended M&A Lower priority ResMed

View entire presentation